Compare RES & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RES | ALVO |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 1995 | 2021 |
| Metric | RES | ALVO |
|---|---|---|
| Price | $6.74 | $4.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $6.40 | ★ $7.20 |
| AVG Volume (30 Days) | ★ 2.1M | 935.0K |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $41,919,000,000.00 | N/A |
| Revenue This Year | $13.23 | $10.83 |
| Revenue Next Year | $0.79 | $20.41 |
| P/E Ratio | $110.42 | ★ $18.20 |
| Revenue Growth | ★ 2216.21 | N/A |
| 52 Week Low | $5.00 | $2.94 |
| 52 Week High | $8.16 | $7.92 |
| Indicator | RES | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 68.97 | 44.65 |
| Support Level | $6.79 | $4.90 |
| Resistance Level | $7.38 | $5.48 |
| Average True Range (ATR) | 0.25 | 0.26 |
| MACD | 0.08 | -0.09 |
| Stochastic Oscillator | 100.00 | 31.75 |
RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. Its operating segment includes Technical Services and Support Services. The Technical Services segment, which generates maximum revenue, comprises service lines that generate revenue based on equipment, personnel, or materials at the well site and are closely aligned with completion and production activities of the customers. The Support Services segment comprises service lines that generate revenue from services and equipment offered off the well site and are closely aligned with the customers' drilling activities.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.